MX9803839A - Derivados de quinolina como inhibidores de fosfodiesterasa tipo iv. - Google Patents

Derivados de quinolina como inhibidores de fosfodiesterasa tipo iv.

Info

Publication number
MX9803839A
MX9803839A MX9803839A MX9803839A MX9803839A MX 9803839 A MX9803839 A MX 9803839A MX 9803839 A MX9803839 A MX 9803839A MX 9803839 A MX9803839 A MX 9803839A MX 9803839 A MX9803839 A MX 9803839A
Authority
MX
Mexico
Prior art keywords
compounds
benzo
type
phosphodiesterase inhibitors
quinoline derivatives
Prior art date
Application number
MX9803839A
Other languages
English (en)
Spanish (es)
Inventor
Rainer Luond
Esteban Pombo Villar
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX9803839A publication Critical patent/MX9803839A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX9803839A 1995-11-14 1998-05-14 Derivados de quinolina como inhibidores de fosfodiesterasa tipo iv. MX9803839A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9523267.4A GB9523267D0 (en) 1995-11-14 1995-11-14 Organic compounds

Publications (1)

Publication Number Publication Date
MX9803839A true MX9803839A (es) 1998-09-30

Family

ID=10783856

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9803839A MX9803839A (es) 1995-11-14 1998-05-14 Derivados de quinolina como inhibidores de fosfodiesterasa tipo iv.

Country Status (17)

Country Link
EP (1) EP0873338A1 (fr)
JP (1) JPH11515000A (fr)
KR (1) KR19990067574A (fr)
CN (1) CN1202170A (fr)
AU (1) AU7570996A (fr)
BR (1) BR9611504A (fr)
CA (1) CA2235126A1 (fr)
CO (1) CO4770973A1 (fr)
CZ (1) CZ149498A3 (fr)
GB (1) GB9523267D0 (fr)
HU (1) HUP9903492A3 (fr)
MX (1) MX9803839A (fr)
PE (1) PE17598A1 (fr)
PL (1) PL326636A1 (fr)
SK (1) SK63998A3 (fr)
TR (1) TR199800851T2 (fr)
WO (1) WO1997018208A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100701904B1 (ko) 1999-08-21 2007-04-02 알타나 파마 아게 Pde 억제제 및 베타 2 아드레날린수용체 작동제의상승적 조합
CN1520313A (zh) 2001-05-23 2004-08-11 ������ҩ��ʽ���� 一种加速骨折愈合的组合物
CA2447618A1 (fr) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Composition pour le traitement regeneratif de la maladie du cartilage
TW200536851A (en) * 2004-01-23 2005-11-16 Amgen Inc Compounds and methods of use
JP2006347936A (ja) * 2005-06-15 2006-12-28 Bayer Cropscience Ag 殺虫性ベンズアニリド類
AR081377A1 (es) 2010-05-10 2012-08-29 Gilead Sciences Inc Compuestos de pirazolopiridina bifuncionales
EP2569285A1 (fr) 2010-05-10 2013-03-20 Gilead Sciences, Inc. Dérivés quinoliniques bifonctionnels
AR093017A1 (es) 2012-10-16 2015-05-13 Janssen Pharmaceutica Nv MODULARES DE RORgT DE QUINOLINILO UNIDOS POR METILENO
JP6250686B2 (ja) 2012-10-16 2017-12-20 ヤンセン ファーマシューティカ エヌ.ベー. Rorγtのヘテロアリール結合させたキノリニルモジュレータ
JP6251277B2 (ja) 2012-10-16 2017-12-20 ヤンセン ファーマシューティカ エヌ.ベー. ROR−ガンマ−tのフェニル結合キノリニルモジュレーター
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
ES2770727T3 (es) 2013-10-15 2020-07-02 Janssen Pharmaceutica Nv Moduladores de quinilonila enlazados a alquilo de ROR(gamma)t
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9624225B2 (en) 2013-10-15 2017-04-18 Janssen Pharmaceutica Nv Quinolinyl modulators of RORγt
EP3813532B1 (fr) * 2018-06-24 2024-02-28 Adama Agan Ltd. Procédé de préparation de quinmérac

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027055D0 (en) * 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
US5455252A (en) * 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines

Also Published As

Publication number Publication date
KR19990067574A (ko) 1999-08-25
CZ149498A3 (cs) 1998-08-12
CA2235126A1 (fr) 1997-05-22
GB9523267D0 (en) 1996-01-17
WO1997018208A1 (fr) 1997-05-22
AU7570996A (en) 1997-06-05
CO4770973A1 (es) 1999-04-30
SK63998A3 (en) 1998-10-07
HUP9903492A3 (en) 2000-08-28
PL326636A1 (en) 1998-10-12
EP0873338A1 (fr) 1998-10-28
CN1202170A (zh) 1998-12-16
PE17598A1 (es) 1998-04-06
TR199800851T2 (xx) 1998-08-21
JPH11515000A (ja) 1999-12-21
BR9611504A (pt) 1999-03-02
HUP9903492A2 (en) 2000-07-28

Similar Documents

Publication Publication Date Title
MX9803839A (es) Derivados de quinolina como inhibidores de fosfodiesterasa tipo iv.
AU6358986A (en) New quinazoline derivatives and a process for their production
HUP0102084A2 (hu) Kinolinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
MX9604020A (es) Arilalquildiazinonas.
IE880213L (en) Purines and imidazoles.
HUP0001285A2 (hu) Proteáz inhibitor hatású pirrolidinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
PL312225A1 (en) Novel chemical compounds exhibiting pde iv inhibiting activity
HUT49612A (en) Process for producing new 3-alkenyl-1-azabicyclo/3.2.0/ hept-2-ene-2-carboxylic acid derivatives and pharmaceutical compositions comprising same
RO115522B1 (ro) Derivaţi de indolină, procedee pentru prepararea acestora, compoziţii farmaceutice care îi conţin şi metodă de tratament
IE810108L (en) IMIDAZO £1,2-a| PYRIDINES
AU5681800A (en) Quinoline derivatives as antibacterials
HUT69407A (en) Process for producing quinolin-4-amine-and 1h-imidazo[4,5-c]quinolin-4-amine derivatives as intermediates
HUT37128A (en) Process for the production of dihydropyridazinone-derivatives, as well as of pharmaceutical preparations containing these derivatives as agent
GB8334494D0 (en) Carbostyril derivatives
HUT43051A (en) Process for preparing pyridine-carboxylic acid derivatives and pharmaceutical compositions containing thereof as active ingredients
HUP9901652A2 (hu) Piperidin-karbonsav-származékok alkalmazása vérglükózkoncentráció csökkentésére alkalmas gyógyszerkészítmények előállítására
IL106128A0 (en) Vitamin d derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
IL104773A0 (en) Naphthalene derivatives,their preparation and pharmaceutical compositions containing them
HUT40101A (en) Process for producing quinolin-carboxylic acid derivatives and pharmaceutical compositions containing them as active agents
GB9011335D0 (en) Indolebutyric acid derivatives and process for preparation thereof
DE68902209D1 (de) Imidazolin-derivate und verfahren zu deren herstellung.
ATE48001T1 (de) Cephemverbindungen, verfahren zu ihrer herstellung und ihre pharmazeutischen praeparate.
HUP0003624A2 (hu) 1,2,3,4-Tetrahidro-benzofuro[3,2-c]piridin-származékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
EP0186023A3 (fr) Dérivés d'acides biliaires, procédé pour leur préparation et compositions pharmaceutiques les contenant
HK1018783A1 (en) BENZO[C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5 α-REDUCTASES INHIBITORS